For Healthcare Professionals

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

clipboard-pencil

About the study

A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Previously untreated metastatic or unresectable, recurrent head and neck squamous cell carcinoma.
  2. Adequate bone marrow function.
  3. Adequate renal and liver function.
  4. Adequate ECOG performance status.

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.
  2. History of (non-infectious) pneumonitis that required steroids or current pneumonitis.
  3. Prior treatment with any anti-CD47 or anti-SIRPα agent.
  4. Prior treatment with anti-PD-1 or PD-L1.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Head and Neck Cancer,Head and Neck Squamous Cell Carcinoma

Age (in years)

18+

Phase

Phase 2

Participants needed

168

Est. Completion Date

Dec 31, 2024

Treatment type

Interventional


Sponsor

ALX Oncology Inc.

ClinicalTrials.gov identifier

NCT04675333

Study number

AT148004

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.